Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL903263 | 0.79 | TDP1 (0.54) | TDP1LMNAALDH1A1MAPK1HIF1A | |
| SCHEMBL2973529 | 0.78 | SMN1; SMN2 (0.57) | LMNALTA4HMMP8SMN1; SMN2 | |
| SCHEMBL1449565 | 0.75 | TDP1 (0.70) | TDP1LMNAALDH1A1MAPK1HIF1A | |
| SCHEMBL13219284 | 0.75 | LMNA (0.50) | TDP1LMNAALDH1A1MAPK1SLC6A3 | |
| Hydrochloric Acid SCHEMBL9114435 | 0.73 | TDP1 (0.68) | TDP1LMNAALDH1A1MAPK1HIF1A | |
| SCHEMBL30823716 | 0.73 | TDP1 (0.68) | TDP1LMNAALDH1A1MAPK1HIF1A | |
| SCHEMBL3162957 | 0.72 | TDP1 (0.66) | TDP1LMNAALDH1A1MAPK1HIF1A | |
| SCHEMBL7292310 | 0.72 | TDP1 (0.78) | TDP1LMNAALDH1A1MAPK1HIF1A | |
| SCHEMBL13201697 | 0.72 | LMNA (0.62) | TDP1LMNAALDH1A1MAPK1KMT2A | |
| SCHEMBL3434670 | 0.72 | LMNA (0.57) | TDP1LMNAALDH1A1MAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768708-B1 | N4 CHELATOR CONJUGATES | GE HEALTHCARE LTD (GB) | 2017-05-17 | — | — | EP | disclosed |
| US-20130189186-A1 | APOPTOSIS IMAGING AGENTS BASED ON LANTIBIOTIC PEPTIDES | GE HEALTHCARE LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| US-20130189186-A1 | APOPTOSIS IMAGING AGENTS BASED ON LANTIBIOTIC PEPTIDES | GE HEALTHCARE LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| WO-2012041862-A1 | APOPTOSIS IMAGING AGENTS BASED ON LANTIBIOTIC PEPTIDES | GE HEALTHCARE LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
| US-7767796-B2 | N4 chelator conjugates | GE HEALTHCARE LIMITED (GB) | 2010-08-03 | — | — | US | disclosed |
| US-20080131368-A1 | N4 Chelator Conjugates | GE HEALTHCARE LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189186-A1 | APOPTOSIS IMAGING AGENTS BASED ON LANTIBIOTIC PEPTIDES | BID, BAD, PEBP1 | TDP1 3153/4885LMNA 796/4885ALDH1A1 4847/4885 |
| US-20080131368-A1 | N4 Chelator Conjugates | TTK, PIGK, HUNK | TDP1 3151/4885LMNA 3431/4885ALDH1A1 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.